Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3. European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 "CREATE".
Schöffski, P Wozniak, A Kasper, B Aamdal, S Leahy, Michael G Rutkowski, P Bauer, S Gelderblom, H Italiano, A Lindner, L
Schöffski, P
Wozniak, A
Kasper, B
Aamdal, S
Leahy, Michael G
Rutkowski, P
Bauer, S
Gelderblom, H
Italiano, A
Lindner, L
Citations
Altmetric:
Abstract
Alveolar soft part sarcoma(ASPS) is an orphan malignancy associated with a rearrangement of transcription factor E3(TFE3), leading to abnormal MET gene expression. We prospectively assessed the efficacy and safety of the tyrosine kinase inhibitor(TKI) crizotinib in patients with advanced or metastatic ASPS.
Authors
Schöffski, P
Wozniak, A
Kasper, B
Aamdal, S
Leahy, Michael G
Rutkowski, P
Bauer, S
Gelderblom, H
Italiano, A
Lindner, L
Hennig, I
Strauss, S
Zakotnik, B
Anthoney, A
Albiges, L
Blay, J
Reichardt, P
Sufliarsky, J
van der Graaf, W
Debiec-Rychter, M
Sciot, R
Van Cann, T
Marréaud, S
Raveloarivahy, T
Collette, S
Stacchiotti, S
Wozniak, A
Kasper, B
Aamdal, S
Leahy, Michael G
Rutkowski, P
Bauer, S
Gelderblom, H
Italiano, A
Lindner, L
Hennig, I
Strauss, S
Zakotnik, B
Anthoney, A
Albiges, L
Blay, J
Reichardt, P
Sufliarsky, J
van der Graaf, W
Debiec-Rychter, M
Sciot, R
Van Cann, T
Marréaud, S
Raveloarivahy, T
Collette, S
Stacchiotti, S
Description
Date
2017-12-05
Publisher
Collections
Keywords
Type
Article
Citation
Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3. European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 "CREATE". 2017 Ann Oncol